永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

未开盘 04-27 16:08:28

3.110

+0.160

+5.42%

最高3.140	最低2.900	成交量19.00万
今开2.960	昨收2.950	日振幅8.14%
总市值19.22亿	流通市值19.22亿	总股本6.18亿
成交额57.88万	换手率0.03%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.11,"timestamp":1777277308802,"preClose":2.95,"halted":0,"volume":190010,"delay":0,"changeRate":0.054237288135593115,"floatShares":618000000,"shares":618000000,"eps":-0.4821588281856157,"marketStatus":"未开盘","change":0.16,"latestTime":"04-27 16:08:28","open":2.96,"high":3.14,"low":2.9,"amount":578819,"amplitude":0.081356,"askPrice":3.11,"askSize":5000,"bidPrice":3.02,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.47527084492582117,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.95,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.574384,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0071","BK0239","BK1574","BK0183","BK0209","BK0191","BK0175","002550","BK0028","300723","688117","BK0196","BK0216","BK0187","06978","600216","000963","LU1969619763.USD","000950","BK1161","688621","LU2328871848.SGD","301281","BK0250","BK0188","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393872","title":"百济神州(06160)与华辉安健签订《合作协议》引进三特异性创新药全球独家开发权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393872","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393872?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，2026 年 4 月 24 日，公司全资子公司百济神州广州与华辉安健签订了一份《合作协议》。此外，华辉安健同意在相关里程碑达成后，向百济神州广州支付其被百济神州广州授予相关知识产权许可的对价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","LU1251922891.USD","BK4526","688235","LU1969619763.USD","BK4588","BK4139","LU1303224171.USD","159992","LU0307460666.USD","06978","LU1770034418.SGD","06160","BK1574","BK1161","BK1583","BK4585","LU1719994722.HKD","BK0239","LU2328871848.SGD","LU0588546209.SGD","BK1588","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630875040","title":"告别乙流多次服药！健康元创新药玛帕西沙韦胶囊或成更优选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2630875040","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630875040?lang=zh_cn&edition=full","pubTime":"2026-04-25 08:24","pubTimestamp":1777076695,"startTime":"0","endTime":"0","summary":"近期，全国流感活动持续攀升，乙型流感强势主导本轮流行季，对公众健康构成显著威胁。中国疾控中心近期发布的全国急性呼吸道传染病哨点监测数据显示，全国流感病毒检测阳性率连续几周上升，北方省份检测阳性率高于南方。　　目前，据了解玛帕西沙韦胶囊已在各大主流医药电商平台上线，患者可便捷咨询购买，有效提升了药品可及性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260425/32173558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK0114","BK0188","BK0077","600380","BK0239","159992","BK0046","06978","BK1161","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629901508","title":"【券商聚焦】申万宏源首予海西新药(02637)“买入”评级 指其大力推进创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2629901508","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629901508?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:42","pubTimestamp":1777012941,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申万宏源发布研报指，首次覆盖海西新药 ，给予“买入”评级，目标价298.28港元。研报指出，海西新药是一家通过仿制药业务已连续5年实现盈利的创新药企业，2025年营业收入达到5.82亿元人民币，同比增长25%，净利润达1.77亿元，同比增长30%。在仿制药业务稳定盈利后，公司大力推进创新药研发。首发适应症骨肉瘤预计2026年上半年开展III期临床研究。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","02637","000166","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629974938","title":"港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629974938","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629974938?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:26","pubTimestamp":1777011981,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英午后涨近6%，截至发稿，涨5.49%，报97.1港元，成交额4458.26万港元。公开数据显示，2025年凯莱英化学大分子CDMO板块实现营业收入10.28亿元，同比增长123.72%，成为公司增长最为迅速的业务单元。公司预计26年多肽PPQ项目将达4个且多肽固相合成产能将从25年底的4.5万升增至26年底的6.9万升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK1574","BK4139","002821","BK0239","VXUS","159992","BK1161","06821","06978","BK4588","LU1328615791.USD","BK4585","BK1191","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU0455707207.USD","LU2097828557.USD","LU2488822045.USD","06978","BK1161","LU2242644610.SGD","06990","LU2097828805.USD","09969","LU2097828631.EUR","06855","01672","159992","01477","LU2097828474.EUR","BK1589","LU0502904849.HKD","LU2097828714.EUR","BK1574","BK1191","LU2328871848.SGD","01801","BK1583","BK1515","02637","LU0196878994.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629707860","title":"什么情况？港股通创新药突遭重挫，龙头领跌12%！520880放量跌4.51%连失多根均线，加仓还是离场？","url":"https://stock-news.laohu8.com/highlight/detail?id=2629707860","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629707860?lang=zh_cn&edition=full","pubTime":"2026-04-24 09:18","pubTimestamp":1776993480,"startTime":"0","endTime":"0","summary":"4月23日，港股继续调整，恒指放量连阴失守26000点。港股通创新药突遭急跌，100%创新药研发标的——港股通创新药ETF华宝收跌4.51%五连阴，失守10日、20日及半年线等3根均线。　　值得关注的是，520880全天宽幅溢价，且交投尤为活跃，全天成交3.8亿元，较上日激增逾95%。　　权重龙头多股重挫为主要拖累，前十成份股中仅石药集团逆市收涨1.71%，康方生物领跌12.66%，三生制药跌9.63%，信达生物、科伦博泰生物跌近6%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-04-24/doc-inhvqfhn3227784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1161","VXUS","BK1574","520880","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629643518","title":"中国创新药“军团”领跑AACR年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2629643518","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629643518?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:00","pubTimestamp":1776985200,"startTime":"0","endTime":"0","summary":"1907年的华盛顿，11位医生与科学家随手组建的“小圈子”，谁也没想到会演变成今天全球癌症研究领域最负盛名的盛会——美国癌症研究协会（AACR）。一百多年后的今天，AACR年会早已不只是一场学术会议，更是全球肿瘤研发的“晴雨表”和“风向标”。对中国生物医药产业而言，AACR也成为观察创新活力与国际化进程的最佳窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716840281.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716840281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880358","title":"东阳光药(06887)：三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629880358?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:25","pubTimestamp":1776939928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东阳光药 发布公告，于2026年4月17日至22日在美国加利福尼亚州圣地亚哥举行的 2026年美国癌症研究协会年会上，本集团以三份壁报形式集中展示了肿瘤治疗领域三款在研管线的最新临床前研究成果。上述三款创新药物在AACR年会上的集中亮相，不仅丰富了本集团的差异化产品管线，更展现了本集团在攻克不可成药靶点及开发下一代免疫疗法方面的技术积累与战略决心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887","159992","BK1574","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629034000","title":"汇率逆风撞上关键药物销售额失色 罗氏卡在专利悬崖与创新药接力的十字路口","url":"https://stock-news.laohu8.com/highlight/detail?id=2629034000","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629034000?lang=zh_cn&edition=full","pubTime":"2026-04-23 14:59","pubTimestamp":1776927545,"startTime":"0","endTime":"0","summary":"按固定汇率计算，总销售额则增长6%。其中制药业务销售额高达114.69亿瑞士法郎，占集团销售额的77.9%，诊断业务销售额32.53亿瑞士法郎，占22.1%。在上一季度曾经令投资者们失望的重磅眼科药物Vabysmo，第一季度实现销售额显著增长13%，并显示出在美国市场可能出现强劲复苏的迹象;此前，罗氏不得不加大资助力度，以帮助患者们获得该药物。罗氏股价今年以来已下跌近5%。罗氏股价今年以来疲软，本质上是市场在交易三重担忧。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1574","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","UGA","VXUS","BK1589","159992","DBO","DRLL","GUSH","BK1161","LU0455707207.USD","USE","BK1583","BK1574","IEO","BNO","01530","OIH","03692","01801","DUG","LU2097828805.USD","BK4570","BK1191","09995","LU2242644610.SGD","LU2097828557.USD","DBC","OILT","LU2488822045.USD","OILU","LU2097828631.EUR","USOI","DBE","VDE","LU2097828474.EUR","LU1969619763.USD","BK1593","06978","DIG","BWET","LU2097828714.EUR","HK0000165453.HKD","PXJ","BK4585","ERX","DRIP","IXC","LU2328871848.SGD","USL","OILK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629104691","title":"晚期乳腺癌创新药德达博妥单抗在华上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2629104691","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629104691?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:57","pubTimestamp":1776859020,"startTime":"0","endTime":"0","summary":"新京报讯（记者王卡拉）4月22日，阿斯利康与第一三共合作开发并引入中国的第二款抗体偶联药物（ADC）注射用德达博妥单抗（商品名：达卓优）在中国正式上市，首批到货将陆续在全国各地医院和药房落地启用。乳腺癌是中国女性最高发的恶性肿瘤之一，仅2022年确诊病例就超过35万例，并造成约7.5万例患者死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223714396528.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223714396528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629204554","title":"创新药赛道走势分化，港股通创新药ETF易方达（159316）全天净申购超1亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629204554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629204554?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:45","pubTimestamp":1776858351,"startTime":"0","endTime":"0","summary":"4月22日，受市场影响，创新药赛道走势分化，港股创新药板块冲高回落低位震荡，A股创新药板块低开高走，截至收盘，恒生港股通创新药指数下跌0.6%，中证创新药产业指数上涨0.8%，资金逆势布局，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)全天净申购超1亿份。招银国际指出，生物医药产业定位跃升为新兴支柱产业，预示全链条政策红利将持续释放，AI制药技术突破与中国创新药出海BD爆发形成双重共振，行业基本面有望加速向好。当前国产创新药出海合作已从单一管线授权升级至平台层面合作，跨国药企对中国医药研发实力的认可度正系统性提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026042200048504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","06978","BK1161","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629506945","title":"广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2629506945","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629506945?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:14","pubTimestamp":1776813269,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日广发基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率15.91%。与上一季度相比，该基金前十大重仓股新增信立泰；并对药明康德增仓222.76万股，为该基金第一大重仓股；艾力斯等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200013520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1808992512.USD","LU2242644610.SGD","LU0456842615.SGD","LU0348766576.USD","LU2125910500.SGD","LU0708995583.HKD","LU1934453819.USD","BK1141","BK1576","LU2488822045.USD","LU2045819591.USD","159992","LU1997244956.HKD","LU1969619763.USD","BK0216","LU1997245177.USD","LU0320764599.SGD","LU1979443071.USD","06978","BK1574","LU2328871848.SGD","BK1583","LU0348767384.USD","BK1161","603259","LU0052750758.USD","02359","LU2495084118.USD","LU1997245094.SGD","LU1046422090.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629725779","title":"银华基金马君旗下银华中证创新药产业ETF一季报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2629725779","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629725779?lang=zh_cn&edition=full","pubTime":"2026-04-21 05:22","pubTimestamp":1776720178,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日银华基金旗下马君 王帅管理的银华中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率19.45%。与上一季度相比，该基金前十大重仓股新增信立泰；并对药明康德增仓365.71万股，为该基金第一大重仓股；百济神州等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100010044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","BK1141","BK1583","LU1969619763.USD","LU0320764599.SGD","LU0052750758.USD","LU1997245094.SGD","159992","LU0348767384.USD","LU2328871848.SGD","LU0456842615.SGD","BK1574","LU1997244956.HKD","LU2488822045.USD","LU1979443071.USD","BK1161","LU1997245177.USD","LU2045819591.USD","LU0348766576.USD","LU2242644610.SGD","603259","BK0216","BK1576","LU0708995583.HKD","02359","LU1808992512.USD","06978","LU2125910500.SGD","LU1046422090.SGD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728871","title":"绿叶制药(02186)创新药LY03015(VMAT2抑制剂╱Sigma-1R激动剂)美国PK桥接临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728871","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628728871?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:09","pubTimestamp":1776686941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，集团自主研发的新分子实体LY03015的美国药代动力学桥接临床试验已完成首例受试者入组。LY03015为全球首个囊泡单胺转运体2 抑制剂和σ-1受体激动剂，目标适应症为治疗迟发性运动障碍和亨廷顿病。LY03015通过靶向VMAT2和Sigma-1R，旨在发挥对于TD和HD两种疾病在“症状控制”和“病理改善”的双重作用。据集团所知，VMAT2抑制剂是目前唯一一类获得美国食品药品监督管理局批准上市的、用于治疗TD和HD的药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","BK4218","PK","BK1583","02186","06978","BK1606","BK4181","159992","BK1574","03015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209911","title":"九典制药：公司正全面推进向创新药研发的战略转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209911","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209911?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:51","pubTimestamp":1776430319,"startTime":"0","endTime":"0","summary":"谢谢九典制药回复：尊敬的投资者：您好！公司正全面推进向创新药研发的战略转型，采取“多个研发中心+多种药物形式+多种合作模式”的策略。公司在中部地区和长三角布局了双创新药研发中心，目前研发平台拥有40余名专业人员，涵盖从药物设计到临床研究的各环节，核心团队具备多个创新药临床及上市申报的成功经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700043115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","BK0239","159992","300705","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628094192","title":"从长期“烧钱”到整体盈利！沙利文：创新药企进入投资价值兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2628094192","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628094192?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:37","pubTimestamp":1776429420,"startTime":"0","endTime":"0","summary":"近期，28家科创板创新药公司集中披露2025年度业绩快报。数据显示，28家公司合计实现营业收入约740亿元，同比增长近30%，创历史新高；归母净利润约16亿元，成功扭转亏损局面，实现了从长期“烧钱”到整体盈利的历史性跨越。约八成公司营收同比增长，六成公司利润端有所好转，百济神州、诺诚健华等多家企业首次实现扭亏为盈，预计将于2026年“摘U”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709251397.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709251397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628168277","title":"参照药预沟通开闸，创新药医保报价打破开“盲盒”模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2628168277","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628168277?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:06","pubTimestamp":1776420360,"startTime":"0","endTime":"0","summary":"近日，国家医保局公示第一批参照药预沟通药品信息，共31个1类创新药，涵盖肿瘤、代谢、自身免疫等领域，涉及恒瑞、信达、亚盛、罗氏、诺华等中外头部药企。从上市情况看，23个为五年内新上市药品，1个为五年内适应症或功能主治发生重大变化的药品，另外7个则为尚未获批上市药品。在业内看来，这是为新一轮医保目录调整做铺垫。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709067641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709067641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277851","title":"长城基金梁福睿：关注创新药行业具备中长期价值、能真正兑现和成长的公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277851","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628277851?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:50","pubTimestamp":1776419400,"startTime":"0","endTime":"0","summary":"近期，国内创新药及创新药产业链持续获得政策强力支持，叠加产业基本面改善与国际化突破，市场普遍看好其长期发展前景。国家药监局3月28日发布的信息显示，今年第一季度，我国创新药对外授权交易额超过600亿美元，接近2025年全年的一半。截至3月27日，今年我国已有10款创新药获批上市，其中2款为进口，8款为国产，创新药取得历史性突破。长城医药产业精选基金经理梁福睿近期就这些问题接受媒体采访，进行了专业剖析。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-04-17/doc-inhuveqy6398552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0689},{"period":"1month","weight":0.1187},{"period":"3month","weight":0.2054},{"period":"6month","weight":0.0367},{"period":"1year","weight":-0.2506},{"period":"ytd","weight":0.0614}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.038921},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}